The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

The present disclosure relates to a class of JAK inhibitor compounds and uses thereof. Specifically, the present disclosure discloses a compound represented by formula (I), isotopically labeled compound thereof, or optical isomer thereof, geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. The present disclosure also relates to the application of the compounds in medicine.

##STR00001##

Provided herein is the use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, disclosed is the use of compounds of formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof; and application thereof. Definition of each group in the formula can be found in the specification for details.

##STR00001##

Provided herein is the use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, disclosed is the use of compounds of formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof; and application thereof. Definition of each group in the formula can be found in the specification for details.

##STR00001##

A portable transdermal administration patch apparatus comprises a communication control device and a pharmaceutical device which is fixed to and arranged at a lower end of the communication control device and electrically connected to the communication control device. The communication control device is formed of a micro-battery, a wireless control device and a micro-controller which are electrically connected. The preparation of the patch apparatus is achieved by: the preparation of medicinal patches and non-medicinal patches, the mounting of electrodes, interfacing with a micro-controller, and the communication control system, and starting administration. The transdermal apparatus is wearable and can be remotely controlled, and is convenient for administration, in particular, for the situations of daily administration for elderly patients with chronic illness and when there are a larger number of admitted inpatients, where a nurse can pre-set the administration time and dose, thus saving time and efforts of medical staff.

A portable transdermal administration patch apparatus comprises a communication control device and a pharmaceutical device which is fixed to and arranged at a lower end of the communication control device and electrically connected to the communication control device. The communication control device is formed of a micro-battery, a wireless control device and a micro-controller which are electrically connected. The preparation of the patch apparatus is achieved by: the preparation of medicinal patches and non-medicinal patches, the mounting of electrodes, interfacing with a micro-controller, and the communication control system, and starting administration. The transdermal apparatus is wearable and can be remotely controlled, and is convenient for administration, in particular, for the situations of daily administration for elderly patients with chronic illness and when there are a larger number of admitted inpatients, where a nurse can pre-set the administration time and dose, thus saving time and efforts of medical staff.

A method of inhibiting a rise in intraneuronal calcium concentration includes administering an effective amount of a cyclic amine derivative represented by formula (I) or a pharmacologically acceptable salt thereof to a subject in need thereof: ##STR00001##
wherein A represents formula (IIa), (IIb) or (IIc): ##STR00002##

A method of inhibiting a rise in intraneuronal calcium concentration includes administering an effective amount of a cyclic amine derivative represented by formula (I) or a pharmacologically acceptable salt thereof to a subject in need thereof: ##STR00001##
wherein A represents formula (IIa), (IIb) or (IIc): ##STR00002##

Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.